Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Affirms Q4 Guidance, Lowers Full-Year Cash Burn Projections

NEW YORK, Jan. 18 (GenomeWeb News) - Galapagos today said that it expects its fourth-quarter 2005 revenues to meet previous guidance of €7.7 million ($9.3 million), and that it expects its full-year cash burn to be lower than its guidance of €7 million.

 

The Belgian drug discovery company said that the successful integration of product lines from BioFocus, which it acquired in October, plus "financial control measures" enabled it to keep cash burn lower than it had anticipated.

 

Galapagos, which trades on the Euronext exchange in Brussels and Amsterdam and the London AiM, said it expects revenues for the full year to increase to €11 million, from €7.8 million in 2004.

 

The company said it plans to publish its full year 2005 results on March 3.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.